US Patent 9,925,150: Rotigotine Transdermal Patch Claims, Expiration, Litigation and Patent Landscape
US Patent 9,925,150 protects a rotigotine transdermal delivery platform based on a solid dispersion of non-crystalline rotigotine free base and polyvinylpyrrolidone, commonly known as PVP, at an approximately 9:4 weight ratio. The patent also covers silicone pressure-sensitive adhesive systems, microreservoir structures, rheological properties, adhesion performance, drug loading and methods for preparing the dispersion.
The patent is directed to formulation and manufacturing architecture rather than to rotigotine as a molecule. Its commercial relevance is concentrated in rotigotine patches that use PVP-stabilized rotigotine free base in silicone adhesive matrices, including Neupro-type systems.
What does US Patent 9,925,150 protect?
US 9,925,150 contains 25 claims divided into five principal categories:
| Claim category |
Claims |
Protected subject matter |
| Stabilization method |
1, 13-19 |
Stabilizing non-crystalline rotigotine free base with PVP at an approximately 9:4 ratio |
| Solid dispersion |
2-6, 20-25 |
Rotigotine/PVP dispersed in an adhesive or other dispersing agent |
| Pharmaceutical composition |
7 |
Composition containing the claimed solid dispersion |
| Transdermal therapeutic system |
8-11 |
Patch containing rotigotine, PVP and compatible silicone adhesive |
| Manufacturing method |
12 |
Preparing a transdermal system using the claimed dispersion |
The independent claims are claims 1, 2, 7, 8, 10 and 12. Claims 3-6, 9 and 11, and claims 13-25, narrow those independent claims through formulation, viscosity, adhesion and structural limitations.
Core chemical limitation: rotigotine free base and PVP
The central limitation is the use of:
- Rotigotine in free-base form;
- A non-crystalline or amorphous rotigotine phase;
- Polyvinylpyrrolidone as stabilizing polymer; and
- An approximately 9:4 weight ratio of rotigotine free base to PVP.
The ratio is approximately 2.25:1 by weight. A product using rotigotine free base and PVP outside the legally construed meaning of "about 9:4" may avoid literal infringement, although the specification and prosecution history would control the permissible range. The claims supplied do not establish a fixed numerical tolerance.
The patent does not broadly claim every rotigotine formulation. A product using a different stabilizing polymer, a crystalline rotigotine form, rotigotine salt, or a materially different polymer ratio would fall outside the literal scope of the core claims unless another limitation or the doctrine of equivalents applied.
How do the independent claims differ?
Claim 1: stabilization method
Claim 1 covers a method for stabilizing rotigotine by providing a solid dispersion containing PVP and non-crystalline rotigotine free base at approximately 9:4.
This is a process claim. It is potentially relevant to manufacturing operations even if the finished patch is not sold in the United States, provided the claimed method is practiced in the United States. It also creates a direct infringement theory against a manufacturer that performs the claimed stabilization process.
The claim does not require a transdermal patch, silicone adhesive, specific drug loading or a defined viscosity. It is therefore broader in some respects than the patch claims.
Claim 2: solid dispersion
Claim 2 covers the product architecture:
- A dispersing agent;
- A dispersed phase;
- Rotigotine free base in the dispersed phase;
- PVP in the dispersed phase; and
- An approximately 9:4 rotigotine-to-PVP ratio.
The claim is not limited to silicone adhesive. Claims 4-6 narrow the product to silicone systems, low rotigotine solubility and microreservoir structures.
Claim 8: transdermal therapeutic system
Claim 8 requires:
- At least one amine-compatible silicone pressure-sensitive adhesive;
- Approximately 0.1 to 3.15 mg/cm² of rotigotine in free-base form;
- PVP; and
- The approximately 9:4 rotigotine-to-PVP ratio.
This is the most commercially targeted independent claim. It maps closely to a drug-in-adhesive transdermal patch using silicone adhesive and stabilized rotigotine free base.
The drug-loading range is broad enough to cover multiple patch strengths if the loading is calculated per unit area. The claim does not state a particular patch size, total patch dose, backing layer, release liner or membrane.
Claim 10: transdermal system containing the dispersion
Claim 10 incorporates the solid dispersion of claim 2 into a transdermal therapeutic system. It does not independently repeat all limitations of claim 8, including the explicit 0.1 to 3.15 mg/cm² range. Claim 11 adds that loading range.
Claim 12: preparation method
Claim 12 covers preparing a transdermal system by first preparing the claimed rotigotine/PVP solid dispersion. It is directed to manufacturing sequence and formulation preparation, not merely to the final marketed patch.
What formulation technologies are protected?
Silicone pressure-sensitive adhesives
Claims 4, 8 and related dependent claims require, or expressly include, silicone pressure-sensitive adhesive. The adhesive must be compatible with the amine functionality of rotigotine. Compatibility is important because rotigotine can interact with adhesive components, potentially affecting drug stability, crystallization, release and patch adhesion.
The patent claims both a single adhesive system and mixtures of adhesives. A competing patch using an acrylate, polyisobutylene or rubber-based adhesive could avoid the silicone-specific claims, although it could still implicate broader solid-dispersion claims if all other limitations are met.
Two-adhesive systems
Claims 5, 14-17 and 20-23 address systems using two adhesives with different complex viscosities. The claimed ranges include:
| Parameter |
Claimed range |
| First adhesive complex viscosity |
40-250 MP |
| Second adhesive complex viscosity |
1-10 MP |
| Mixed dispersing agent complex viscosity |
5-25 MP |
| Alternative solid-dispersion viscosity |
5-15 MP |
These limitations provide design specificity but also create potential noninfringement routes. A formulation that uses one adhesive, a different viscosity profile or a viscosity outside the claimed range may avoid the narrower claims while remaining exposed under broader claims.
Microreservoir structure
Claims 6 and 9 cover rotigotine and PVP contained in a multitude of microreservoirs. This limitation distinguishes a microstructured dispersion from a conventional homogeneous drug-in-adhesive system.
A patch with a uniform molecular or particulate distribution may not meet the microreservoir limitation. The outcome would depend on how "microreservoirs" is construed and on the physical characterization of the accused product.
Adhesion performance
Claims 18 and 24 recite peel adhesion values:
- 3-16 N/50 mm at a thickness of 50 g/m²; and/or
- 14-26 N/50 mm at a thickness of 150 g/m².
Claims 19 and 25 recite static shear adhesion of 20-150 minutes.
These are performance limitations. They may be difficult to assess from public product information because infringement testing would require controlled laboratory protocols, defined substrates, temperature, dwell time, coating weight and test standards.
When does US Patent 9,925,150 lose exclusivity?
US 9,925,150 was granted on March 27, 2018. Its listed priority chain controls the ultimate patent-term calculation. The patent is associated with UCB's rotigotine transdermal formulation technology and has a term extending into approximately 2030, subject to the official USPTO term calculation, any patent-term adjustment, terminal disclaimer and post-grant legal events.[1]
| Event |
Date |
| Patent grant |
March 27, 2018 |
| Expected ordinary term endpoint |
Approximately 2030 |
| Patent status relevant to launch |
Must be verified against USPTO Patent Center and any terminal disclaimer |
| Regulatory exclusivity |
Separate from patent term and generally runs on a different timetable |
A patent expiration date does not itself establish generic launch permission. A generic applicant also must address FDA approval requirements, any Orange Book listing, pediatric exclusivity, other listed patents and litigation-related injunctions or settlements.
What is the Orange Book status of US 9,925,150?
The relevant FDA reference product is Neupro, a rotigotine transdermal system marketed by UCB.[2] The Orange Book can list patents that claim the drug, formulation, delivery system or an approved method of use. A listing, if present, affects ANDA certification and Paragraph IV litigation under the Hatch-Waxman Act.
US 9,925,150 is formulation-focused and is the type of patent that may be relevant to an Orange Book strategy for a rotigotine patch. The patent claims do not cover rotigotine broadly as an active ingredient. They target a specific stabilized dispersion and patch construction.
The practical Orange Book questions are:
- Whether US 9,925,150 is currently listed against the applicable Neupro NDA;
- Whether the listing covers all approved strengths or only particular presentations;
- Whether later UCB patents are also listed;
- Whether a generic applicant filed a Paragraph IV certification; and
- Whether FDA approval is blocked by a 30-month stay or affected by a settlement.
The patent record alone does not establish the current Orange Book listing status or the existence of a Paragraph IV notice. Those are FDA and litigation-record questions, not conclusions that can be drawn solely from the claims.
Which companies are challenging the rotigotine patent estate?
A complete competitor or Paragraph IV analysis requires current FDA Orange Book data, ANDA records and PACER or district-court docket review. The supplied patent claims do not identify a challenger, ANDA filer or litigation defendant.
Potential commercial challengers would include companies developing generic rotigotine transdermal systems, especially manufacturers with experience in complex patches. A conventional ANDA applicant would need to address both pharmaceutical equivalence and the patent estate covering:
- Rotigotine free base;
- PVP stabilization;
- Silicone adhesive compatibility;
- Drug loading;
- Microreservoir architecture;
- Adhesion performance; and
- Manufacturing methods.
A noninfringement strategy could use a different polymer, a different rotigotine-to-polymer ratio, a non-silicone adhesive or a different physical dispersion. An invalidity strategy would focus on anticipation and obviousness based on earlier rotigotine patches, amorphous solid dispersions, PVP stabilization, silicone adhesive systems and known patch manufacturing methods.
What patent litigation affects US 9,925,150?
No litigation outcome can be inferred from the claim language. For diligence purposes, the relevant litigation questions are:
| Issue |
Business significance |
| Paragraph IV notice |
Indicates an ANDA applicant's invalidity or noninfringement position |
| 45-day suit period |
Determines whether the NDA holder can trigger a statutory stay |
| 30-month stay |
May delay FDA approval of an ANDA |
| Claim construction |
Defines the scope of "about 9:4," "non-crystalline," "microreservoirs" and viscosity terms |
| Settlement agreement |
May establish an authorized generic date or delayed entry date |
| Injunction |
Can prevent commercial launch after approval |
| Formulation redesign |
May reduce exposure to the patent while increasing development cost |
A settlement can permit launch before patent expiration, but its terms are typically confidential or disclosed only through regulatory and antitrust filings. No specific settlement should be assumed without a docket or agreement.
How strong is the patent estate for rotigotine patches?
US 9,925,150 has meaningful commercial scope because it combines a key stabilizer ratio with a patch-compatible adhesive system. Its strength is not uniform across all claim groups.
| Claim group |
Relative strength |
Main vulnerability |
| Claim 1 stabilization method |
Moderate to strong |
Prior-art process disclosures and construction of "about 9:4" |
| Claim 2 solid dispersion |
Strong if ratio and phase are distinctive |
Prior art on rotigotine/PVP dispersions |
| Claims 4-5 silicone systems |
Moderate |
Design-around using another adhesive or viscosity profile |
| Claims 6 and 9 microreservoirs |
Narrower |
Product may lack the claimed physical structure |
| Claim 8 patch system |
Commercially important |
Alternative polymer, adhesive or drug loading |
| Claims 18-19 adhesion properties |
Narrow |
Test-method dependence and non-overlapping performance |
| Claim 12 manufacturing method |
Potentially strong against process suppliers |
Limited visibility into competitors' internal manufacturing |
The patent is strongest against a patch that replicates the claimed formulation architecture. It is weaker against a product that uses a different polymer or adhesive platform and does not practice the ratio, phase or structural limitations.
How does this patent compare with the broader Neupro patent estate?
The Neupro estate can be divided into four layers:
- Core rotigotine and transdermal delivery patents;
- Patch formulation and adhesive patents;
- Stability and crystallization-control patents;
- Regulatory and method-of-use protections.
US 9,925,150 belongs primarily to the second and third layers. It does not independently establish exclusivity over Parkinson's disease treatment, restless legs syndrome treatment or rotigotine pharmacology.
UCB's commercial protection therefore depends on cumulative coverage. A generic may avoid one patent but remain exposed to another formulation or delivery patent. Conversely, if US 9,925,150 is the principal unexpired formulation patent and a generic successfully avoids its limitations, the remaining barrier may be regulatory rather than patent-based.
What manufacturing and geographic barriers exist?
The claims have territorial effect in the United States. They do not directly block manufacture, sale or use outside the United States unless corresponding foreign family members are in force.
Manufacturing exposure is highest where a supplier:
- Produces the rotigotine/PVP dispersion in the United States;
- Supplies the dispersion to a U.S. patch manufacturer;
- Performs the claimed adhesive-mixing process;
- Uses the claimed loading or viscosity ranges; or
- Imports a finished patch into the United States.
Foreign family members must be assessed separately in Europe, Japan, Canada, Australia and other commercial markets. Patent term, claim amendments, opposition proceedings and validity outcomes may differ by jurisdiction.
What is the generic launch risk for rotigotine patches?
The principal launch scenarios are:
| Scenario |
Likely result |
| Generic copies the 9:4 rotigotine/PVP system and silicone architecture |
High infringement risk |
| Generic uses PVP but materially changes the ratio |
Depends on construction of "about 9:4" and equivalents |
| Generic uses a different stabilizing polymer |
Lower exposure to the core claims |
| Generic uses non-silicone adhesive |
Avoids silicone-specific claims, but not necessarily claim 2 |
| Generic uses a different physical dispersion |
May avoid microreservoir claims |
| Generic enters after patent expiry |
Patent risk materially declines, subject to other patents |
| Generic settles with UCB |
Entry date depends on agreement terms |
A generic developer should treat the ratio, physical form and polymer identity as critical freedom-to-operate variables. Adhesive rheology and peel/shear performance are secondary but potentially decisive claim limitations.
Key Takeaways
- US 9,925,150 targets rotigotine transdermal formulation technology, not rotigotine generally.
- The central limitation is an approximately 9:4 weight ratio of rotigotine free base to PVP.
- The patent covers stabilization methods, solid dispersions, silicone adhesive systems, microreservoirs, patch loading and manufacturing methods.
- Claim 8 is the principal commercial patch claim.
- Claims directed to viscosity, peel adhesion and static shear are narrower and more susceptible to design-around.
- The patent is associated with a term extending into approximately 2030, subject to the official USPTO term record.
- Paragraph IV, Orange Book and litigation conclusions require current FDA and court-docket verification.
- The main generic strategies are changing the polymer, ratio, adhesive, physical dispersion or manufacturing process.
- Biosimilar analysis is not relevant because rotigotine is a small-molecule active ingredient delivered through a transdermal system.
- Commercial risk depends on the full UCB patent family, not US 9,925,150 in isolation.
FAQs
Does US 9,925,150 cover all rotigotine patches?
No. It covers patches meeting specific formulation and structural limitations, particularly the rotigotine free-base/PVP ratio and, in some claims, silicone adhesive, drug loading, microreservoir and rheological requirements.
Can a generic use rotigotine hydrochloride instead of rotigotine free base?
A salt-based product would not literally meet the free-base limitations in these claims. It would require separate analysis under the doctrine of equivalents and against other patents.
Is PVP alone enough to infringe US 9,925,150?
No. PVP must be present with the claimed rotigotine free base and approximately 9:4 weight ratio, together with the other limitations of the asserted claim.
Do the viscosity claims cover every silicone adhesive mixture?
No. Claims 5, 17 and 23 require specified adhesive combinations and viscosity ranges. A formulation outside those ranges may avoid the narrower claims, subject to the remaining claims.
Does patent expiration automatically permit FDA approval of a generic patch?
No. FDA approval, Orange Book certifications, regulatory exclusivity, other listed patents and litigation restraints may still affect launch timing.
References
- United States Patent and Trademark Office. (2018). U.S. Patent No. 9,925,150, solid dispersion comprising rotigotine and polyvinylpyrrolidone.
- U.S. Food and Drug Administration. (2007). Neupro (rotigotine) transdermal system prescribing information.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
- U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs, Neupro NDA 021829.
